134 related articles for article (PubMed ID: 21356164)
41. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer.
Piawah S; Venook AP
Cancer; 2019 Dec; 125(23):4139-4147. PubMed ID: 31433498
[TBL] [Abstract][Full Text] [Related]
42. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road.
Ríos-Hoyo A; Monzonís X; Vidal J; Linares J; Montagut C
Front Pharmacol; 2024; 15():1398419. PubMed ID: 38711991
[TBL] [Abstract][Full Text] [Related]
43. Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer.
Underwood PW; Ruff SM; Pawlik TM
Cells; 2024 Jan; 13(3):. PubMed ID: 38334637
[TBL] [Abstract][Full Text] [Related]
44. Anti-angiogenesis in colorectal cancer therapy.
Yang Z; Zhang X; Bai X; Xi X; Liu W; Zhong W
Cancer Sci; 2024 Mar; 115(3):734-751. PubMed ID: 38233340
[TBL] [Abstract][Full Text] [Related]
45. Nanostructures for site-specific delivery of oxaliplatin cancer therapy: Versatile nanoplatforms in synergistic cancer therapy.
Bagheri M; Zandieh MA; Daryab M; Samaei SS; Gholami S; Rahmanian P; Dezfulian S; Eary M; Rezaee A; Rajabi R; Khorrami R; Salimimoghadam S; Hu P; Rashidi M; Ardakan AK; Ertas YN; Hushmandi K
Transl Oncol; 2024 Jan; 39():101838. PubMed ID: 38016356
[TBL] [Abstract][Full Text] [Related]
46. Response to osimertinib in a colorectal cancer patient with an
Buzard B; Douglass L; Gustafson B; Buckley J; Roth M; Kujtan L; Bansal D
World J Gastrointest Oncol; 2023 Oct; 15(10):1829-1834. PubMed ID: 37969405
[TBL] [Abstract][Full Text] [Related]
47. Clusterin Expression in Colorectal Carcinomas.
Téllez T; Martin-García D; Redondo M; García-Aranda M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834086
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of the bone morphogenetic protein pathway suppresses tumor growth through downregulation of epidermal growth factor receptor in MEK/ERK-dependent colorectal cancer.
Shimizu S; Kondo J; Onuma K; Coppo R; Ota K; Kamada M; Harada Y; Tanaka Y; Nakazawa MA; Tamada Y; Okuno Y; Kawada K; Obama K; Coffey RJ; Fujiwara Y; Inoue M
Cancer Sci; 2023 Sep; 114(9):3636-3648. PubMed ID: 37357017
[TBL] [Abstract][Full Text] [Related]
49. Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines.
Shao H; Wells A
Front Oncol; 2023; 13():1163504. PubMed ID: 37333807
[TBL] [Abstract][Full Text] [Related]
50. Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives.
Manzi J; Hoff CO; Ferreira R; Pimentel A; Datta J; Livingstone AS; Vianna R; Abreu P
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37296986
[TBL] [Abstract][Full Text] [Related]
51. Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review.
Kumar A; Gautam V; Sandhu A; Rawat K; Sharma A; Saha L
World J Gastrointest Surg; 2023 Apr; 15(4):495-519. PubMed ID: 37206081
[TBL] [Abstract][Full Text] [Related]
52. Cyclooxygenase and Lipoxygenase Gene Expression in the Inflammogenesis of Colorectal Cancer: Correlated Expression of EGFR, JAK STAT and Src Genes, and a Natural Antisense Transcript, RP11-C67.2.2.
Kennedy BM; Harris RE
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190308
[TBL] [Abstract][Full Text] [Related]
53. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S; El-Sabban M; Doughan S; Abou-Kheir W
World J Gastroenterol; 2023 Mar; 29(9):1395-1426. PubMed ID: 36998426
[TBL] [Abstract][Full Text] [Related]
54. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments.
Tang YL; Li DD; Duan JY; Sheng LM; Wang X
World J Gastroenterol; 2023 Feb; 29(6):926-948. PubMed ID: 36844139
[TBL] [Abstract][Full Text] [Related]
55. Current Targeted Therapy for Metastatic Colorectal Cancer.
Ohishi T; Kaneko MK; Yoshida Y; Takashima A; Kato Y; Kawada M
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675216
[TBL] [Abstract][Full Text] [Related]
56. A study of gene variation in All-
Tao H; Shen M; Zhang X; Wang M; Wu Y; Sun H; Ling C; Yang Y; Chen K; Li D
J Gastrointest Oncol; 2022 Dec; 13(6):3009-3024. PubMed ID: 36636055
[TBL] [Abstract][Full Text] [Related]
57. Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges.
Al-Hujaily EM; Al-Sowayan BS; Alyousef Z; Uddin S; Alammari F
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430176
[TBL] [Abstract][Full Text] [Related]
58. Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies.
Moshawih S; Lim AF; Ardianto C; Goh KW; Kifli N; Goh HP; Jarrar Q; Ming LC
Biomolecules; 2022 Jun; 12(7):. PubMed ID: 35883434
[TBL] [Abstract][Full Text] [Related]
59. Modular and mechanistic changes across stages of colorectal cancer.
Rahiminejad S; Maurya MR; Mukund K; Subramaniam S
BMC Cancer; 2022 Apr; 22(1):436. PubMed ID: 35448980
[TBL] [Abstract][Full Text] [Related]
60. Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification.
Ginghina O; Hudita A; Zamfir M; Spanu A; Mardare M; Bondoc I; Buburuzan L; Georgescu SE; Costache M; Negrei C; Nitipir C; Galateanu B
Front Oncol; 2022; 12():856575. PubMed ID: 35356214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
